CTSB and Alzheimer disease: Here, we demonstrate that the number of cathepsin B+ cells, and the activity of cathepsin B is significantly increased in people who have EOAD compared with those undergoing healthy ageing, supporting the proposed role of the enzyme as a potential therapeutic target in AD.